Interleukin-24 is correlated with differentiation and lymph node numbers in rectal cancer

Table 4 Survival analysis in the lymph node metastatic rectal cancer patients

	n	5-yr disease specific survival	P value	5-yr disease free survival	P value	5-yr local recurrence free survival	P value	5-yr distant metastasis free survival	P value
Age (yr)
Less than 60	48	60.4	0.963	51.8	0.918	60.3	0.683	57	0.483
60 or older	42	60.7		53.1		59.5		66.3
Sex
Male	47	60.3	0.742	49.2	0.528	57.4	0.903	60.3	0.760
Female	43	60.8		55.8		62.8		62.6
Differentiation
Well	46	74.9	0.060	59.3	0.333	73.8	0.008	64.7	0.459
Moderately	34	48.5		45.7		50		59.8
Poorly	10	33.3		44.4		30		55.6
T stage
T1	1	100	0.441	100	0.427	100	0.385	100	0.298
T2	8	87.5		87.5		75		87.5
T3	79	57.6		48.2		58.2		57.3
T4	2	50		50		50		100
N stage
N1a	24	82.6	0.004	73.7	0.003	74.8	0.001	77	0.015
N1b	26	59.4		55.7		69.2		68.5
N2a	16	68.8		50		68.8		56.3
N2b	24	34.2		29.3		29.2		40.8
Stage
IIIa	8	100	0.002	100	0.002	100	0.230	100	0.009
IIIb	59	64.6		54.1		80.1		63
IIIc	23	35.8		30.7		64.5		42.7
VEGF expression
Negative	26	53.1	0.801	50	0.851	73.3	0.629	64.1	0.791
Positive	64	61.9		53.5		81.1		60.5
IL-24 expression
Negative	40	59.2	0.759	50.7	0.890	60	0.496	60.7	0.849
Positive	50	34.7		53.9		59.9		61.6

VEGF: Vascular endothelial growth factor; IL-24: Interleukin-24.